Slide 1: Third Quarter 2025 Operating & Financial Results Conference Call
Third Quarter 2025 Operating & Financial Results Conference Call / Webinar Nov 13th, 2025 9AM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amend ed, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave CFO 01 Introduction CEO and President 02 2025 Q3 Highlights 03 Financial Highlights 04 Q&A 2
Slide 4: Q3 2025 Highlights 1 of 3
2025 ✓ LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved with 48% clinical benefit rate in 3 Quarter evaluable cancer patients at or above therapeutic dose rd threshold; marked tumor reductions observed in patients with DNA damage repair mutations including CHK2, ATM,
Slide 5: Q3 2025 Highlights 2 of 3
2025 ✓ LP-284 clinical data showcased at 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress, generating interest from the biopharma and clinical communities and initiating 3 Quarter rd discussions for combination therapy potential. Highlights ✓ KOL-hosted scientific webinar on LP-184 Phase 1a
Slide 6: Q3 2025 Highlights 3 of 3
2025 3 Quarter rd ✓ AI platform commercial readiness demonstrated at Highlights inaugural AI for Biology and Medicine symposium, showcasing RADR® platform modules as deployable tools for biopharma partners. 3of 3 ✓ Disciplined capital management maintained with approximately $12.4 million in cash, c
Slide 7: LP-184 Phase 1a Trial Achieved All Primary Endpoints with Robust Safety Profile
LP-184 Phase 1a Trial Achieved All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors TR IAL R E S U LT H IGHL IG HT S • Completion of enrollment of phase 1 trial (NCT05933265) meeting all its primary endpoints • Demonstrated a robust safe
Slide 8: Planned Clinical Trials – LP-184 Phase 1b/2 Trials
Planned Clinical Trials – LP-184 Phase 1b/2 Trials informed by RADRⓇ AI Insights Trial Indication Market potential Trial Size Trial Highlights Phase 1b/2 • Granted FDA Fast Track Designation for monotherapy of LP-184 Monotherapy & Combination with $4+Bn ~60 • Monotherapy Trial: Evaluating optimal do
Slide 9: Clinical Trial – The Harmonic Phase 2 Trial for LP-300
Clinical Trial – The HarmonicTM Phase 2 Trial for LP-300 A growing indication with limited treatment options Logo Description automatically generated with low confidence NCT05456256 NCT05456256 Trial Highlights • Completed Japanese patient cohort enrollment ahead of schedule at multiple clinical sit
Slide 10: First-In-Human Trial for LP-284
LP-284 Highlights from NHL Clinical Trial & Potential New Indications Phase 1a trial for recurrent NHLs with scarce therapeutic options and potential in SLE / Lupus First-In-Human Trial for LP-284 Highlights LP-284 + Rituximab: A Potential Next-Generation B-Cell Depleting Therapy for SLE • Heavily p
Slide 11: AI-Powered RADR Modules for Oncology
A proprietary integrated experimental biology, oncology-focused, machine-learning-based drug development platform AI-Powered RADR® Modules for Oncology 200+ 80%+ Billion Prediction * Success Drug Discovery and Development Discover mechanism Characterize specialized m1 m5 attributes of a molecule 130
Slide 12: Zeta – The Multi-Agentic Co-Scientist & AI System For Rare Cancers
Zeta – The Multi-Agentic Co-Scientist & AI System For Rare Cancers Zeta addresses the fundamental challenge in rare cancer research and drug development where critical insights are scattered across disconnected data sources. Our platform integrates curated databases and external sources into an agen
Slide 13: Strategic Expansion of ML, AI, and Data Engineering Teams in India
Lantern Strategy to Accelerate AI Platform Growth and Capabilities with Strategic Expansion of ML, AI, and Data Engineering Teams in India Expansion Overview • Establishing dedicated machine learning and data engineering teams in India • 2x–3x increase in technical team size expected in the coming q
Slide 14: Lantern's Diverse & Unique AI Driven Pipeline of Drug Programs
Lantern’s Diverse & Unique AI Driven Pipeline of Drug Programs Lantern has 10 disclosed drug programs including the Phase 2 HarmonicTM trial Lantern Pharma (NASDAQ: LTRN) Orphan Rare Pediatric Fast Program Indication Discovery Preclinical Phase 1a Phase 1b Phase II Designation Disease Track LP-300 N
Slide 15: Financial Updates Q3 2025
Financial Updates Q3 2025 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended September 30, (unaudited) 09/30/2025 12/31/2024 2025 2024 (unaudited) Operating expenses: Cash, Cash Equivalents & 12,362,576 24,013,063 Marketable Securities General and administrative $ 1,
Slide 16: 2025-26 Objectives
2025-26 Objectives A Breakthrough Year for Lantern ● Complete Phase 1a clinical trial for LP-184; pursue Phase 1b/2 and investigator led trial(s) T ● Advance enrollment in first-in-human clinical trial for LP-284 in NHL + other cancers O ● Report initial clinical data for Asian cohort in the Harmoni
Slide 17: Connect With Us
NASDAQ: LTRN CONNECT WITH US CONNECT WITH US IR Contact: IR Contact: IR@lanternpharma.com IR@starlighttthera.com 1-972-277-1136 www.lanternpharma.com www.starlightthera.com @LanternPharma @Starlight_Thera linkedin.com/company/lanternpharma linkedin.com/company/starlightthera linkedin.com/company/lan